NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday, 14 March 2024

**Location:** Via Zoom

**Attendees**

# Committee members present

1. Professor Tom Clutton-Brock (Chair) Present for all items
2. Mr James Tysome (Vice Chair) Present for all items
3. Mr Christopher Adams Present for all items
4. Professor Dhiraj Tripathi Present for all items
5. Dr Jon Bell Present for items 4, 5, 6, 7, and 8 (part 1)
6. Dr Jurjees Hasan Present for all items
7. Ms Kathleen Ford Present for all items
8. Mr Mahmoud Elfar Present for all items
9. Mr Marwan Habiba Present for all items
10. Professor Matt Bown Present for all items
11. Mr Mustafa Zakkar Present for all items
12. Ms Noemi Muszbek Present for all items except item 9 (part 2)
13. Mr Paddy Storrie Present for all items
14. Mr Patrick Farrell Present for all items
15. Dr Paula Whittaker Present for all items
16. Dr Sandeep Singh Randhawa Present for all items
17. Professor Tim Kinnaird Present for all items
18. Ms Veena Soni Present for all items

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Adviser, IPP

Amy Crossley – HTA Adviser, IPP

Dr Anastasia Chalkidou – Associate Director, IPP

Professor Anthony Akobeng – Consultant Clinical Advisor, IPP

Corrina Purdue – Project Manager, IPP

Charlotte Pelekanou – HTA Adviser, MTEP

Deonee Stanislaus – Coordinator, IPP

Frances Nixon – Health Technology Assessment Advisor, Diagnostics

Haider Shamsi - Associate Health Technology Assessment Analyst, Appraisals

Helen Gallo – Senior Health Technology Assessment Analyst, IPP

Lakshmi Mandava – Health Technology Assessment Analyst, IPP

Louisa Robinson – Health Technology Assessment Analyst, IPP

Michael Kertanegara – Associate Health Technology Assessment Analyst, IPP

Rachael Cazaly – Medical Editor, Publishing

Sana Issa – Coordinator, Corporate Office

Sarah Bromley – Senior Medical Editor, Publishing

Xia Li – Health Technology Assessment Analyst, IPP

Zoe Jones – Administrator, IPP

# 

# External group representatives present:

Francesca Torasso, Anika Therapeutics Present for item 4

Sandy Havercroft, Anika Therapeutics Present for item 4

Carrie Harthill, Geistlich Pharma AG Present for item 4

Dr Despoina Natsiou Schmiady, Geistlich Pharma AG Present for item 4

Adrian Ford, In2med Present for item 4

Lauren Wheat, Ideal Medical Solutions Ltd Present for item 5

Alessia Blundo, Elesta SpA Present for item 5

Harith Rajagopalan, Fractyl Health Present for item 8

John Amatruda, Fractyl Health Present for item 8

Helen Hill, Terumo Europe Present for item 9

Bryan Holvoet, Terumo Europe Present for item 9

Neil Turner, BSCI Present for item 9

Dr Jacob Wright, BSCI Present for item 9

# Clinical, Patient & NHS England experts present:

Nick Howells, Consultant Orthopaedic Knee Surgeon, North Bristol NHS Trust Present for item 4

1. Introduction to the meeting
   1. The Chair welcomed members of the committee and other attendees present to the meeting.
   2. The Chair noted apologies from Augusto Azuara-Blanco, Conrad Harrison, Dawn Lee, Karen Nugent, Matthew Metcalfe, and Stuart Smith.
2. News and announcements
   1. None.
3. Minutes from the last meeting
   1. The committee noted that in section 8.2.1 of the minutes it stated that the committee decision was reached through a vote by members, whereas the decision in the meeting was reached via a consensus. They also suggested editorial changes to be made such as ensuring all company names were formatted consistently.
4. NNP of IP1098/2 Scaffold insertion without cultured cell implantation for repairing symptomatic chondral knee defects
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical experts, members of the public and company representatives from Anika Therapeutics, Geistlich Pharma AG, and In2med.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Paula Whittaker, who gave a presentation on the safety and efficacy of Scaffold insertion without cultured cell implantation for repairing symptomatic chondral knee defects.
  1. Part 2 – Closed session

Company representatives, clinical experts and members of the public were asked to leave the meeting: 10:03.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1972 Image-guided percutaneous laser ablation for primary and secondary liver tumours
   1. Part 1 – Open session
      1. The Chair welcomed the members of the public and company representatives from Ideal Medical Solutions and Elesta SpA.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Mustafa Zakkar, who summarised the comments received during the consultation on the draft guidance for Image-guided percutaneous laser ablation for primary and secondary liver tumours.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 11:05.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP963/2 Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* James Tysome declared a financial interest as he performs endoscopic sinus surgery on both NHS and private patients, although he does not use steroid eluting stents or spacers.
* It was agreed that his declaration would not prevent James Tysome from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced James Tysome, who gave a presentation on the safety and efficacy of Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Briefs of IP2014 Electrically stimulated intravesical therapy for Interstitial Cystitis
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Sandeep Singh Randhawa declared a professional interest as he is a GP with a specialist interest in Urology but does not perform this procedure.
* It was agreed that this was not a conflict and would not prevent Sandeep Singh Randhawa from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Mahmoud Elfar, who gave a presentation on the safety and efficacy of Electrically stimulated intravesical therapy for Interstitial Cystitis.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Public Consultation comments of IP1846 Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes
   1. Part 1 – Open session
      1. The Chair welcomed the members of the public and company representatives from Fractyl Health.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Kathleen Ford, who summarised the comments received during the consultation on the draft guidance for Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 12:38.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1314 Selective internal radiation therapy (SIRT) for neuroendocrine tumours that have metastasised to the liver
   1. Part 1 – Open session
      1. The Chair welcomed the members of the public and company representatives from Terumo Europe and BSCI.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Noemi Muszbek declared a past direct financial interest as the company she works for has previously worked on a number of projects with Sirtex. The last project finished in 2023.
* It was agreed that her declaration would prevent Noemi Muszbek from participating in this section of the meeting and she was asked to leave the meeting for part 2 of the discussion.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Matt Bown, who summarised the comments received during the consultation on the draft guidance for Selective internal radiation therapy (SIRT) for neuroendocrine tumours that have metastasised to the liver.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 13:06.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 11/04/2024 and will start promptly at 9am.